The Active Site

Nicotine is usually discussed as an addictive drug. But in 1959, researchers noticed something unexpected: people who smoked appeared less likely to develop Parkinson’s disease. That observation survived decades of scrutiny and eventually led to animal experiments, memory studies, nicotine patches, and major clinical trials. This investigation follows that evidence from the original anomaly to the latest human research to determine what nicotine actually does to the brain—and whether its neuroprotective reputation has been earned.Time Stamps0:00 – Intro1:44 – Reverse causation theory2:32 – The Swedish snus study4:00 – Animal trials: mice vs. monkeys5:16 – Nicotine's effect on the brain7:35 – The NIC-PD trial9:04 – The MIND trial11:31 – The 2009 paper that predicted the failure12:55 – What the evidence actually shows

Microplastics have been detected in human brain tissue, and in 2025 one study produced a number that spread around the world: roughly a spoonful of plastic in the brain. But the closer you look at how that number was produced, the stranger the story becomes. This investigation follows the evidence to find out what is actually accumulating in our brains, how much is there, and whether it is doing harm.Time Stamps0:00 – The spoonful of plastic claim1:00 – What the first brain study found3:35 – An experiment inside living brain vessels5:29 – The dementia finding6:54 – A second human brain study8:49 – How scientists measure plastic in tissue10:15 – Another way plastic could affect the brain12:02 – Where things stand now

BPC-157 is now used as a recovery peptide for tendon injuries, muscle strains, and stubborn joint problems. Some people report remarkable results, while others feel nothing. But its story did not begin in sports medicine. It traces back through human stomach fluid, an old Yugoslav research program, pharmaceutical development, and decades of experiments that still leave major parts of the peptide’s history unresolved. This investigation follows that evidence from the beginning to find out what BPC-157 actually is, what it may be doing, and how it became the healing peptide.Time stamps:0:00 – What BPC-157 really is2:02 – How it got its name4:50 – What the animal studies show8:33 – The science that still doesn't add up10:28 – A stability problem nobody talks about12:17 – The human trial history13:43 – A missing piece in the story15:17 – What the evidence still doesn't prove16:29 – Where things stand now

There is an element sitting in your brain right now, and nobody has established how much you are supposed to have.  It may shape how you think, how you act, and whether your mind holds up as you age. Last year a Harvard lab placed it near the center of Alzheimer's, arguing that running short of it may be one of the first things that goes wrong in the diease. It is already sold as the next longevity compound, the thing that finally protects the aging brain, and the people selling it have a real paper behind them. This investigation takes that case apart study by study to find out how much of it holds. The question sounds simple. The answer, as always, is not.00:00 – Intro: Lithium and the Brain01:57 – Lithium's Origin as a Bipolar Drug04:55 – The Brain Growth Claim10:10 – Where the Evidence Breaks Down12:12 – The Harvard Brain Study15:36 – Should You Take Lithium?18:04 – New Trial Starting This Fall

Creatine is one of the most-studied supplements in the world, taken by millions of people who have been told for years it is about as safe as anything on the shelf. Then, within weeks of each other, two peer-reviewed studies reached opposite conclusions about what it does to cancer. One found that creatine helped cancer spread faster through the body. The other found that creatine helped the body fight cancer off. Same molecule, serious labs, and results that cannot both be simple. This investigation starts with the alarming study, published only days ago, and takes it apart: what it actually measured, what it measured only in mice, and what it never measured in a human at all. Then it does what the headlines will not, setting that study against the wider body of research to answer the only question that matters for the person taking it. Is creatine feeding cancer, or is something more ordinary going on?0:00 – Introduction1:04 – The New Study on Creatine and Cancer3:22 – Other Studies Findings6:38 – The Real Explanation8:41 – A Study on Cancer Patients9:54 – What's Still Unknown

There are tests now that claim to measure how old you really are. Not the number on your birth certificate, but your biological age, the idea being that two people born on the same day can be aging at different speeds, and that a blood or saliva sample can tell them apart. It starts with a discovery from fifteen years ago, that chemical marks on your DNA shift as you get older. Since then, the clocks built on it have moved fast, from reading your age, to forecasting how long you have left, to scoring each organ, to scoring individual cell types from a single vial of blood. So what does one of these numbers actually measure, how good have they become, and would one handed to your doctor change anything about what happens to you?0:00 – Can You Really Measure Your Age?1:04 – The Cheek Swab That Started It4:00 – Reading Death, Not Birthdays5:45 – The Hidden Flaw7:51 – Your Organs Age Differently8:36 – 11 Ages, One Blood Draw10:06 – 40 Clocks, One Vial11:36 – The Missing Proof14:15 – The Verdict*Citations can be found on my website

For decades the reassuring story about tattoos was that the ink stays put: a permanent mark, sealed in the skin, chemically done with your body. It isn't. Pigment migrates out of the skin and lodges in your lymph nodes, carrying the carcinogens it came with, and it stays there for the rest of your life. That's not in dispute. What is in dispute is whether any of it actually causes cancer, and in 2024 and 2025 several teams finally ran the studies. They came back contradicting each other, one country finds tattoos raise melanoma risk, another finds the opposite, and the strongest study designs find nothing at all. So what does the evidence actually show, where's the real risk, and who's regulating what goes into the bottle?0:28 The stained node no one could explain2:01 What's actually in tattoo ink3:28 The body's immune response to ink7:23 Ink and vaccine response8:42 Where the ink migrates to12:30 Tattoos and cancer risk14:44 Conflicting skin cancer data16:03 A confounding factor in the data17:27 The risk of laser removal19:32 How tattoo ink is regulated23:35 Practical takeaways

For most of a decade, vitamin D came with a warning: take it on its own, and the calcium it raises ends up in your arteries instead of your bones. The fix, supposedly, is vitamin K2. The claim is unusually specific for supplement advice, specific enough to put to randomized, placebo-controlled trials with arterial calcium scored on CT before and after. The trials came back. They don't agree with each other. So what does the evidence actually show, and did a 2026 trial change the answer?0:00 – The trio everyone's told to take together1:09 – The magnesium story2:47 – Why K2 is different3:45 – Putting it to the test4:15 – What the trials found5:55 – What you should actually do6:40 – K2: cutting through the hype7:06 – When it makes sense, when it doesn't

For most of the last century, apigenin was a footnote — a yellow pigment in chamomile and parsley, studied mostly by people cataloguing the antioxidants in plants. In the last few years it has become one of the most-recommended compounds on the internet: the third ingredient in the famous sleep stack, a fixture in longevity protocols built around NAD+, and an addition to formulas aimed at cellular aging itself. But how does the evidence hold up?0:00 - Introduction0:45 - Why apigenin is everywhere right now2:30 - How apigenin works4:30 - Human anxiety trials6:00 - Second discovery8:00 - What the marketing gets wrong10:45 - Where the evidence actually stands12:20 - Should you take it?

For decades, magnesium sat in the supplement aisle as a mineral for muscle cramps, sleep, and general nutrition. Around 2010, that changed. A branded form called magnesium L-threonate launched on the back of a 2010 MIT rodent paper, and a new category was born — magnesium for the brain. Fifteen years later, that category has expanded to include other brand-targeted forms, premium price points, and confident claims about cognition, memory, and synaptic density. In this investigation, we review the science underneath those claims.IN THIS INVESTIGATIONWhat two papers from 1984 actually said about magnesium and the brainWhy magnesium concentrates differently in brain fluid than in blood, and what that implies for supplementationThe 2010 MIT paper that launched the brand-targeted magnesium category, and the question it didn't answerWhat you find when you trace the authorship of the rodent studies that "independently confirmed" the originalThe magnesium acetyl taurate line and what a 2026 head-to-head comparison reveals about form-specific brain deliveryEvery human trial on magnesium L-threonate, who funded each one, and the structural feature they all shareThe 2024 paper that directly measured magnesium inside living human brains for the first time in twenty-five yearsWhat the ordinary forms — citrate, chloride, oxide — have actually demonstrated in independent human trialsWhy a failed 2007 traumatic brain injury trial matters for everything that followedThe single piece of evidence the brand-targeted magnesium story has never producedWhat to do if you take magnesium for cognitive reasonsSubscribe for more investigations.